• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA warns Magellan Diagnostics on lead tests

October 23, 2017 By Brad Perriello

The FDA today warned Meridian Bioscience (NSDQ:VIVO) subsidiary Magellan Diagnostics based on the Class I recall of its lead poisoning tests, accusing the company of failing to protect patients after it learned of problems with the tests.

The May recall, which was expanded in July, involves Magellan’s LeadCare, LeadCare II, Ultra and Plus products. The tests may underestimate blood lead levels and provide inaccurate results with venous blood samples.

Today’s warning letter came after the federal safety watchdog inspected Magellan’s plant in North Billerica, Mass., from May 10 to June 29. The inspections turned up numerous violations, the FDA said, including failure to submit medical device reports to the FDA regarding discrepancies in test results and alteration of two of the tests after winning FDA clearance “by changing the amount of time that the mixture of blood samples with the reaction substance (reagent) must sit before analysis in an effort to reduce the risk of falsely low results.”

“Magellan did not report these significant changes to the FDA for review and evaluation, as required,” the agency said.

“The FDA has serious concerns about Magellan Diagnostics’ actions after learning about inaccuracies in results using its blood lead testing devices – tests that the American people depend on,” Donald St. Pierre, acting director of the Office of In Vitro Diagnostics & Radiological Health and deputy director of new product evaluation in the FDA’s Center for Devices & Radiological Health, said in prepared remarks.

“The evidence uncovered during the inspection shows that the company put patients at risk after it recognized that its tests could provide inaccurate results and failed to take appropriate steps to report this issue and work through a strategy to effectively mitigate problems with the FDA. We take the violations described in the warning letter very seriously and are continuing to work with the company to investigate the root cause of the falsely low test results.”

Magellan has until Nov. 10 to notify the FDA about specific steps it’s taken to address the violations and prevent their recurrence, the FDA said.

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: magellandiagnostics

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS